Blueshift Asset Management LLC Purchases Shares of 13,817 Bruker Corporation (NASDAQ:BRKR)

Key Points

• Blueshift Asset Management LLC has acquired 13,817 shares of Bruker Corporation, valued at approximately $577,000, according to its recent filing with the SEC.
• Bruker announced a quarterly dividend of $0.05 per share, effective June 27th, representing a 0.5% yield.
• The company reported a 9.6% increase in revenue year-over-year, totaling $801.4 million, and its current EPS stands at $0.47.

Blueshift Asset Management LLC bought a new stake in Bruker Corporation (NASDAQ:BRKR - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm bought 13,817 shares of the medical research company's stock, valued at approximately $577,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Pinnacle Bancorp Inc. acquired a new stake in Bruker during the 1st quarter valued at $29,000. Allworth Financial LP raised its holdings in shares of Bruker by 92.4% in the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after buying an additional 364 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Bruker by 274.9% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after acquiring an additional 800 shares in the last quarter. Fifth Third Bancorp raised its holdings in Bruker by 54.2% during the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock worth $46,000 after purchasing an additional 390 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its position in shares of Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after purchasing an additional 196 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Bruker Stock Performance

BRKR stock traded down $3.27 during midday trading on Monday, reaching $34.72. 8,149,176 shares of the company were exchanged, compared to its average volume of 3,479,107. The firm has a market capitalization of $5.26 billion, a price-to-earnings ratio of 66.77, a price-to-earnings-growth ratio of 2.56 and a beta of 1.16. The business has a 50-day moving average price of $39.94 and a two-hundred day moving average price of $43.35. Bruker Corporation has a one year low of $32.07 and a one year high of $72.94. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.57 and a quick ratio of 0.74.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.11). Bruker had a return on equity of 19.47% and a net margin of 2.31%. The firm had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. During the same period in the prior year, the business posted $0.52 EPS. The firm's quarterly revenue was down .4% compared to the same quarter last year. Equities research analysts forecast that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Monday, June 16th were given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, June 16th. Bruker's dividend payout ratio is 38.46%.

Insider Activity

In other news, CEO Frank H. Laukien bought 2,608 shares of the stock in a transaction dated Friday, June 6th. The shares were bought at an average cost of $38.36 per share, with a total value of $100,042.88. Following the completion of the transaction, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. This trade represents a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 27.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on BRKR shares. Barclays reduced their target price on Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Monday. Jefferies Financial Group decreased their target price on Bruker from $70.00 to $60.00 and set a "buy" rating for the company in a research note on Monday. Wells Fargo & Company dropped their target price on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Citigroup cut their price target on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday. Finally, The Goldman Sachs Group lowered their price objective on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $53.10.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.